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Abstract 
Purpose:  Leuprolide is a safe and effective treatment of estrogen receptor positive, 
premenopausal breast cancer.  Data from the SOFT/TEXT trials solidified leuprolide, in 
combination with an aromatase inhibitor, as an effective hormonal treatment for premenopausal 
breast cancer.  However, the efficacy of monthly leuprolide depot compared to every three-
month leuprolide depot in combination with an aromatase inhibitor in premenopausal women 
with estrogen receptor positive breast cancer is unclear. 
Patients and Methods:  In this single center retrospective study, 201 patients were enrolled 
between Jan 1st, 2015, and Oct 1st, 2016; 100 were included in the leuprolide 7.5mg monthly 
injection plus aromatase inhibitor group and 101 in the leuprolide 22.5mg every 3-month 
injection plus aromatase inhibitor group.  The primary endpoint was the proportion of patients 
who achieved ovarian ablation, defined as an estradiol concentration less than 40 pg/mL and an 
FSH concentration of 23-116 mU/mL after 3 months of treatment.  Significance threshold was a 
P<0.05 (two-sided).  Secondary endpoints included disease free survival and overall survival at 
one year follow-up, and adverse events reported during treatment. 
Results:   All patients in the leuprolide monthly arm achieved ovarian ablation compared to 100 
(99%) of the 101 patients in the every 3-month arm (P=1).  The disease free survival rate at 1 
year was 95% in the monthly leuprolide arm and 97% in the every 3-month arm (P=0.75).  The 
overall survival rate at 1 year was 100% in the leuprolide monthly arm and 99% in the every 3-
month arm (P=1).  The most common treatment-related adverse events between the two groups 
were musculo-skeletal pain, hot flashes, fatigue, and insomnia. 
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Conclusion:  Leuprolide acetate depot administered every 3 months is as efficacious and 
tolerable as monthly injection, in combination with an aromatase inhibitor for patients with 
premenopausal, hormone receptor positive breast cancer. 
INTRODUCTION  
 Leuprolide acetate Depot (Lupron®) is an intramuscular injection that is currently used 
off-label for premenopausal ovarian ablation in women with breast cancer who are estrogen 
receptor positive and on an aromatase inhibitor.  It is an agonist of gonadotropin releasing 
hormone (GnRH) and acts as a potent inhibitor of gonadotropin secretion.  Continuous 
administration results in suppression of ovarian steroidogenesis due to decreased levels of 
luteinizing hormone (LH) and follicle stimulating hormone (FSH) with subsequent decrease in 
estrogen levels.1  It is available in many different dosages and administration schedules and also 
carries several FDA indications, including treatment of prostate cancer.  However, leuprolide 
acetate currently does not carry an FDA approval for the treatment of breast cancer.  Despite this, 
there have been several large, multicenter, randomized-controlled trials that have proven 
adjuvant treatment of estrogen receptor positive breast cancer in premenopausal woman with a 
GnRH analogue is an effective therapy.3-5   
 Based on the current literature, there has been no study to date evaluating different 
administration schedules of leuprolide acetate depot in combination with an aromatase inhibitor 
as adjuvant treatment in premenopausal, estrogen receptor-positive breast cancer.  We report the 
results of a single institution experience comparing once monthly leuprolide depot to every 
three-month leuprolide depot in combination with an aromatase inhibitor in premenopausal 
women with estrogen receptor positive breast cancer. 
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METHODS 
Patients 
 Eligibility in the trial required documented premenopausal status.  Inclusion criteria were 
histologically proven operable breast cancer, and tumor that expressed estrogen or progesterone 
receptors in at least 10% of the cells, as assessed with the use of immunohistochemical testing.  
All patients must have been 18 years of age or older, undergone either a total mastectomy with 
subsequent optional radiotherapy or breast-conserving surgery with subsequent radiotherapy, and 
received adjuvant ovarian suppression in combination with an aromatase inhibitor for at least 1 
year.  Women who underwent bilateral oophorectomy or ovarian irradiation were excluded. 
Design 
 This study was designed as a retrospective chart review of patients identified from a 
Cerner generated report based on administration of leuprolide acetate in the infusion clinic at the 
Indiana University Melvin and Bren Simon Cancer Center and surrounding infusion centers in 
Indianapolis, Indiana.  Patients were separated into two treatment arms based on a documented 
physician order and administration of: leuprolide acetate depot 7.5 mg intramuscular injection 
monthly or leuprolide acetate depot 22.5 mg intramuscular injection every 3 months.   
 The primary endpoint was the proportion of patients who achieved ovarian ablation, 
defined as an estradiol concentration of less than 40 pg/mL and an FSH concentration of 23-116 
mIU/mL after 3 months of treatment.  Secondary endpoints included the following: disease free 
survival, defined as the time from receiving the first dose of leuprolide acetate depot to the 
appearance of invasive recurrence of breast cancer (local, regional, or distant), invasive 
contralateral breast cancer, second (nonbreast) invasive cancer, or death without breast cancer 
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recurrence or second invasive cancer; overall survival, defined as the time from randomization to 
death from any cause; and safety, defined as the incidence of any grade adverse events reported 
while receiving treatment.  For patients who did not have an end-point event, the times were 
censored at the date of a year after initial treatment date. 
Study Oversight 
 The trial protocol was designed by the lead author and was approved by the institutional 
review board at the Indiana University Melvin and Bren Simon Cancer Center in Indianapolis, 
Indiana.  The first author contributed to the collection of data, statistical analysis, and 
interpretation of the results.  All the authors approved the final version of the manuscript, and 
assume responsibility for the adherence of the study protocol and for the accuracy and 
completeness of the data and analyses reported.  No funder had any role in the design, conduct, 
analysis, or interpretation of the study or in the writing of this report. 
Statistical analysis 
 The statistical analysis plan for this study is to compare the proportion patients who 
achieved ovarian ablation between the two groups with the hypothesis that there would be no 
difference.  Differences in baseline characteristics were analyzed using the Pearson Chi-Square 
test for all categorical data and the student t-test for all continuous data.  Kaplan-Meier estimates 
of time-to-event end points were calculated.  Log-rank test was used to calculate P values 
comparing the two groups.  All tests were two sided and a P<0.05 was considered statistically 
significant.  The statistical testing was performed using Statistical Package for Social Sciences 
Windows Version 21 (SPSS Inc., Chicago, IL, USA). 
RESULTS 
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Study Population 
 From between Jan 1st, 2015, and Oct 1st, 2016 a total of 201 patients met eligibility 
criteria for the study; 100 patients in the leuprolide 7.5 mg monthly arm and 101 patients in the 
leuprolide 22.5 mg every 3 months arm.  The characteristics at baseline of the  patients who were 
included are shown in Table 1.  The median age at first dose of adjuvant hormonal therapy was 
40 years.  Node positive disease was present in 37% of patients overall, and in 39% and 35% of 
the leuprolide monthly and every 3 month arms respectively.  There was no significant 
difference between groups with respect to age, prior chemotherapy, tumor grade, lymph node 
involvement, tumor size, HER-2 status, or prior endocrine therapy.  The cohort of patients who 
received prior endocrine therapy had been treated with tamoxifen to assess tolerance to hormonal 
therapy or as a bridge to a GnRH agonist plus aromatase inhibitor.   
Efficacy 
 Three months after the first dose of leuprolide depot, all patients in the 7.5 mg monthly 
group achieved ovarian ablation and all but one patient in the 22.5 mg every 3-month group 
achieved ovarian ablation (P=1).  The distribution of estradiol and FSH levels between the 2 
cohorts at three month follow-up are reported in Table 2.  At 1 year follow-up, 9 patients had 
disease recurrence or second invasive disease or died.  The rate of disease free survival at 1 year 
was 95%  among patients who received leuprolide 7.5 mg monthly as compared with  96%  
among those who received leuprolide 22.5 mg every three months (P=0.75) (Figure 1).   Death 
was reported in 1 patient in the leuprolide 22.5 mg every 3-months; the difference was not 
significant. 
Adverse Events 
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After one year follow-up of all patients in this study, 95% of patients experienced one or more 
side effects related to treatment with either leuprolide acetate or the aromatase inhibitor.  The 
most common side effect reported, per chart review, across both arms was muscolo-skeletal 
symptoms (90%) such as arthralgia (Table 3).  Many of the side effects related to the 
administration of leuprolide that were reported are hot flashes, insomnia, fatigue, depression, and 
vaginal dryness.  These adverse effects were expected following the administration of 
combination hormonal therapy with leuprolide and an aromatase inhibitor based on previous 
reports.3-5 
DISCUSSION 
 This study demonstrates that the leuprolide acetate 22.5 mg intramuscular injection is as 
efficacious and tolerable as the monthly 7.5 mg formulation, in combination with an aromatase 
inhibitor.  Almost all patients, with the exception of one, achieved ovarian ablation in the two 
arms by month three of treatment.  This is comparable to the original research by Boccardo and 
colleagues, who were the first to evaluate the endocrinological and clinical activity of a slow-
release formulation of leuprolide acetate in breast cancer patients.2  A total of 50 pre- or 
perimenopausal patients with early- or late-stage breast cancer who were candidates for 
endocrine treatment were included in the study and randomly allocated to receive either 
3.75 mg of leuprolide acetate every month or 11.25 mg of leuprolide acetate every 3 
months.  In all, 23 patients were allocated to the monthly formulation and 27, to the 3-monthly 
formulation. There was no evidence of any difference in clinical outcome or drug-induced side 
effects, hot flushes being recorded in about 50% of patients in both groups.  All endocrine 
parameters, particularly estradiol levels, were suppressed to a similar extent.  These results are 
validated in our study, however different doses of leuprolide acetate depot were used and 
Boccardo’s study did not use combination GnRH agonists with an aromatase inhibitor.  Our 
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institution uses the approved prostate cancer doses of leuprolide acetate depot instead of the off-
label doses used in the previous study.  Previous large scale, randomized, controlled trials such 
as The TABLE Study have also used the lower dose of 11.25 mg leuprolide every-3-months 
when studied in combination with tamoxifen versus chemotherapy plus tamoxifen.3  This leaves 
some area of uncertainty in terms of which dose of GnRH agonist is optimal as other trials such 
as the SOFT/TEXT trials utilized a different GnRH agonist in the form of triptorelin.  Triptorelin 
was dosed in this study in accordance with the FDA approved prostate cancer dosing of 3.75 mg 
intramuscularly every 28 days.4,5 
While there appears to be no difference in disease free survival, overall survival, or 
adverse events, these results must be interpreted with caution as our study was not randomized 
nor stratified for stage, chemotherapy received, age, grade, or HER2 status.  The SOFT/TEXT 
trials solidified GnRH agonists as a definitive option in adjuvant therapy for premenopausal, 
estrogen receptor positive breast cancer.4,5  The primary analysis of the combined data tested the 
hypothesis that adjuvant therapy with an aromatase inhibitor, exemestane, improved disease-free 
survival, as compared with tamoxifen, among premenopausal women treated plus ovarian 
suppression in the form of monthly triptorelin.  The results revealed that at 5 years, patients who 
received exemestane plus ovarian suppression has superior disease free survival and less 
recurrence compared to tamoxifen plus ovarian suppression.  Because these results were 
published recently, it wasn’t until 2 years ago we saw a shift in prescribing habits of leuprolide 
acetate depot at our institution.  Therefore, we are unable to capture more long term survival data 
at 5 years, versus 1 year in our study, of follow-up at this time.  Of note, the one patient who did 
not achieve ovarian ablation in the every 3-month leuprolide group did not have disease 
recurrence or die at 1 year follow-up.  This patient, however, was only 28 years of age.  In total, 
there were 7 patients across both groups who were less than 30 years of age. 
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The retrospective design comes with inherent limitations.  Our patient population was 
small and a single institutional experience compared to larger randomized, multicenter trials of 
adjuvant hormonal therapy in breast cancer patients.  However, our study was powered to find a 
significant difference in the primary outcome.  There were also some data points that were 
unable to be captured because we must rely on documentation in patient charts.  Accuracy and 
documentation of adverse events such as injection site pain was unable to be collected because of 
this.  A future randomized, prospective study is warranted to confirm the result of this study and 
to allow for a longer follow-up period.   
In conclusion, leuprolide acetate depot administered every 3 months is as efficacious and 
tolerable as monthly injection, in combination with an aromatase inhibitor for patients with 
premenopausal, hormone receptor positive breast cancer.  Prescribing leuprolide acetate depot 
22.5 mg intramuscularly every three months for patients may allow for less infusion chair time, 
cost savings, and higher patient satisfaction. 
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Table 1. 
Baseline Characteristics 
Characteristic Leuprolide Depot 
7.5mg 
N=100 (%) 
Leuprolide Depot 
22.5mg 
N=101 (%) 
P value 
Age (SD) 39 (7.2) 40.1 (7.7) 0.33 
Prior Chemotherapy 53 (53) 53 (52.5) 0.94 
Tumor grade    
Grade 1 27 (27) 25 (24) 0.91 
Grade 2 47 (47) 49 (48.5) 0.83 
Grade 3 25 (25) 24 (23.8) 0.84 
Lymph node involvement    
0 60 (60) 65 (64.4) 0.52 
1-3  27 (27) 25 (24.8) 0.72 
4+  12 (12) 10 (9.9) 0.63 
Tumor size    
<1 cm 19 (19) 16 (15.8) 0.56 
1-2 cm 50 (50) 51 (50.5) 0.94 
2-5 cm 28 (28) 28 (27.7) 0.97 
>5 cm 2 (2) 5 (5) 0.45 
HER-2 status    
Positive 14 (14) 16 (15.8) .71 
Prior endocrine therapy    
Yes 33 (33) 33 (32.7) 0.96 
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Figure 1. 
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Table 2. 
Distribution of Estradiol and FSH at 3 Month Follow-up 
 
 Leuprolide Depot 
7.5mg 
Estradiol levels 
(pg/mL) 
Leuprolide Depot 
22.5mg 
Estradiol levels 
(pg/mL) 
Leuprolide Depot 
7.5mg 
FSH levels 
(mIU/mL) 
Leuprolide Depot 
22.5mg 
FSH levels 
(mIU/mL) 
Median 19.2 22.8 32.2 35.6 
Mean (SD) 18.7 (±2.5) 24.7 (±4.1) 34 (±3.5) 39.1 (±4.1) 
Range 12.1-25.6 12.3-43 8.9-85.1 12.1-110.3 
E2<30 100% 99% - -  - -  
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Table 3.  
Adverse Effects 
Adverse effect Leuprolide Depot 
7.5mg 
N=100 (%) 
Leuprolide Depot 
22.5mg 
N=101 (%) 
P value 
Hot flashes 83 (83) 87 (86.1) 0.54 
Depression 46 (46) 45 (44.6) 0.84 
Insomnia 56 (56) 53 (52.5) 0.51 
Fatigue 68 (68) 66 (65.3) 0.69 
Hypertension 26 (26) 23 (22.8) 0.59 
Musculo-skeletal 92 (92) 90 (89.1) 0.48 
Vaginal dryness 46 (46) 49 (48.5) 0.72 
Nausea 30 (30) 27 (26.7) 0.61 
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